The Latest Cardiac and Vascular News
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2018. The Company reported global revenue of $44.7 million in the second quarter of 2018, a decrease of 7.9% from $48.6 million in the second […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced 1-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) registry as reported on Saturday, June 23rd at the 2018 Society for Vascular Surgery Annual Meeting. The LUCY study […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffry Fecho as the Company’s Chief Quality Officer, effective as of June 25, 2018 (the “Effective Date”). John Onopchenko, Chief Executive Officer of Endologix, […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John Onopchenko as the Company’s Chief Executive Officer, effective immediately. Dan Lemaitre, Chairman of the Board of Directors of Endologix, Inc., commented, “We are very pleased to welcome […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the results of a study, which was presented by Marc Schermerhorn, M.D., Chief of Vascular Surgery at Beth Israel Deaconess Medical Center, on the podium at the Late-Breaking Aortic Trials Session during […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and registries studying polymer endovascular aneurysm repair (Polymer EVAR) using Ovation® Abdominal Stent Graft Systems. ENCORE is a pooled, […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS2 IDE Confirmatory Clinical Study of the investigational Nellix® EndoVascular Aneurysm Sealing (EVAS) System by Sajjad M. Hussain, M.D., Chief of the Department of Vascular Surgery […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott is stepping down as the Company’s Chief Executive Officer. To facilitate a smooth transition, Mr. McDermott has committed to remaining in his current role until a successor is found. Daniel T. […]
IRVINE, Calif.–(BUSINESS WIRE)– Endologix Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today the completion of enrollment in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study. The objective of the 75-patient study is to evaluate the safety and effectiveness of […]
IRVINE, Calif.–(BUSINESS WIRE)– Endologix Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Greg Morrow as the Company’s Chief Marketing Officer, effective immediately. Mr. Morrow brings to Endologix a wealth of executive marketing experience in medical devices. Most recently, he led the Coronary […]
